Literature DB >> 8608783

Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat.

G A Gudelsky1.   

Abstract

The extracellular concentration of dopamine in the striatum and medial prefrontal cortex of the rat was determined following the systemic administration of sigma receptor ligands. The (+)-benzomorphan, (+)-pentazocine, significantly increased the extracellular concentration of dopamine in the striatum also was produced by the (+)-, but not the (-)-, enantiomer of N-allylnormetazocine, as well as by the non-benzomorphans 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoothyl-piper idi ne (DUP 734) and (-)-butaclamol. In contrast, the dopamine concentration was unaffected by di-o-tolylguanidine and markedly suppressed by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine (3-PPP). Finally, the (+)-pentazocine-induced elevation of the extracellular concentration of dopamine was not suppressed by an inhibitor of the dopamine transporter, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine (GBR 12909). Thus, benzomorphan, e.g., (+)-pentazocine and (+)-N-allylnormetazocine, and non-benzomorphan, e.g., DUP 734 and (-)-butaclamol, sigma receptor ligands appear to facilitate dopamine release from nigrostriatal, and presumably mesocorticolimbic, neurons through a non-transporter-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608783     DOI: 10.1016/0014-2999(95)00415-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

2.  Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine.

Authors:  Rae R Matsumoto; Su-Min Li; Jonathan L Katz; William E Fantegrossi; Andrew Coop
Journal:  Drug Alcohol Depend       Date:  2011-03-21       Impact factor: 4.492

3.  Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists.

Authors:  Takato Hiranita; Maddalena Mereu; Paul L Soto; Gianluigi Tanda; Jonathan L Katz
Journal:  Neuropsychopharmacology       Date:  2012-11-28       Impact factor: 7.853

Review 4.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

5.  Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis.

Authors:  Linda Garcés-Ramírez; Jennifer L Green; Takato Hiranita; Theresa A Kopajtic; Maddalena Mereu; Alexandra M Thomas; Christophe Mesangeau; Sanju Narayanan; Christopher R McCurdy; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2010-10-15       Impact factor: 13.382

6.  Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.

Authors:  Yakup Albayrak; Kenji Hashimoto
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-08

7.  Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain.

Authors:  T Kobayashi; K Matsuno; S Mita
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex.

Authors:  Benjamin Gronier; Susanna Waters; Henrik Ponten
Journal:  J Neural Transm (Vienna)       Date:  2013-03-07       Impact factor: 3.575

9.  A Role for Sigma Receptors in Stimulant Self Administration and Addiction.

Authors:  Jonathan L Katz; Tsung-Ping Su; Takato Hiranita; Teruo Hayashi; Gianluigi Tanda; Theresa Kopajtic; Shang-Yi Tsai
Journal:  Pharmaceuticals (Basel)       Date:  2011

10.  Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.

Authors:  Yakup Albayrak; Kenji Hashimoto
Journal:  Psychiatry Investig       Date:  2013-10-24       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.